530239 Stock Overview
A clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Suven Life Sciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹120.80 |
| 52 Week High | ₹169.00 |
| 52 Week Low | ₹75.95 |
| Beta | 1.62 |
| 11 Month Change | -2.30% |
| 3 Month Change | -18.68% |
| 1 Year Change | 45.33% |
| 33 Year Change | 28.72% |
| 5 Year Change | -61.63% |
| Change since IPO | 359.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| 530239 | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 0.2% | 1.2% | 0.3% |
| 1Y | 45.3% | 48.2% | 27.3% |
Return vs Industry: 530239 underperformed the Indian Life Sciences industry which returned 47.9% over the past year.
Return vs Market: 530239 exceeded the Indian Market which returned 27.2% over the past year.
Price Volatility
| 530239 volatility | |
|---|---|
| 530239 Average Weekly Movement | 7.3% |
| Life Sciences Industry Average Movement | 6.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 530239 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 530239's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 141 | Venkat Jasti | www.suven.com |
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders.
Suven Life Sciences Limited Fundamentals Summary
| 530239 fundamental statistics | |
|---|---|
| Market cap | ₹26.34b |
| Earnings (TTM) | -₹1.46b |
| Revenue (TTM) | ₹84.15m |
313.1x
P/S Ratio-18.0x
P/E RatioIs 530239 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 530239 income statement (TTM) | |
|---|---|
| Revenue | ₹84.15m |
| Cost of Revenue | ₹8.24m |
| Gross Profit | ₹75.91m |
| Other Expenses | ₹1.54b |
| Earnings | -₹1.46b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.69 |
| Gross Margin | 90.20% |
| Net Profit Margin | -1,734.89% |
| Debt/Equity Ratio | 0% |
How did 530239 perform over the long term?
See historical performance and comparison